Association Between GLP-1 Receptor Agonists and Incidence of Lung Cancer in Treatment-Naïve Type 2 Diabetes.
作者信息
Song Junmin, Cali Daylan Ayse Ece, Chi Kuan-Yu, Prem Anand Dharshana, Chang Yu, Chiang Cho-Han, Cheng Haiying
机构信息
Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
出版信息
J Gen Intern Med. 2025 Mar;40(4):973-976. doi: 10.1007/s11606-024-09076-z. Epub 2024 Oct 4.
Abstract
摘要
相似文献
1
Association Between GLP-1 Receptor Agonists and Incidence of Lung Cancer in Treatment-Naïve Type 2 Diabetes.初治2型糖尿病患者中GLP-1受体激动剂与肺癌发生率的关联
J Gen Intern Med. 2025 Mar;40(4):973-976. doi: 10.1007/s11606-024-09076-z. Epub 2024 Oct 4.
2
SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline.钠-葡萄糖协同转运蛋白 2 抑制剂或胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病成人患者：临床实践指南。
BMJ. 2021 May 11;373:n1091. doi: 10.1136/bmj.n1091.
3
Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies.胰高血糖素样肽-1受体激动剂与2型糖尿病患者的心力衰竭：随机和观察性研究的系统评价与荟萃分析
BMC Cardiovasc Disord. 2016 May 11;16:91. doi: 10.1186/s12872-016-0260-0.
4
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.钠-葡萄糖共转运蛋白 2（SGLT-2）抑制剂和胰高血糖素样肽-1（GLP-1）受体激动剂治疗 2 型糖尿病：随机对照试验的系统评价和网络荟萃分析。
BMJ. 2021 Jan 13;372:m4573. doi: 10.1136/bmj.m4573.
5
Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data.胰高血糖素样肽-1受体激动剂与胰腺癌风险：利用真实世界数据进行目标试验模拟
J Natl Cancer Inst. 2025 Mar 1;117(3):476-485. doi: 10.1093/jnci/djae260.
6
Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists and Sodium/Glucose Cotransporter 2 Inhibitors in Preventing Chronic Kidney Failure and Mortality in Patients With Type 2 Diabetes and CKD.胰高血糖素样肽-1受体激动剂与钠/葡萄糖协同转运蛋白2抑制剂在预防2型糖尿病合并慢性肾脏病患者慢性肾衰竭及死亡方面的比较疗效
Am J Kidney Dis. 2025 Apr 29. doi: 10.1053/j.ajkd.2025.03.016.
7
Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with kidney outcomes in patients with type 2 diabetes: A systematic review and network meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂、胰高血糖素样肽 1 激动剂和二肽基肽酶 4 抑制剂与 2 型糖尿病患者肾脏结局的关系：系统评价和网络荟萃分析。
PLoS One. 2022 Apr 14;17(4):e0267025. doi: 10.1371/journal.pone.0267025. eCollection 2022.
8
9
GLP-1 receptor agonists and the risk for cancer: A meta-analysis of randomized controlled trials.胰高血糖素样肽-1受体激动剂与癌症风险：随机对照试验的荟萃分析
Diabetes Obes Metab. 2025 Aug;27(8):4454-4468. doi: 10.1111/dom.16489. Epub 2025 May 29.
10
Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: A retrospective observational study.使用胰高血糖素样肽-1受体激动剂的2型糖尿病成人患者的营养缺乏与肌肉流失：一项回顾性观察研究。
Obes Pillars. 2025 Jun 10;15:100186. doi: 10.1016/j.obpill.2025.100186. eCollection 2025 Sep.
引用本文的文献
1
GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity.胰高血糖素样肽-1受体激动剂与肥胖成年人的癌症风险
JAMA Oncol. 2025 Aug 21. doi: 10.1001/jamaoncol.2025.2681.
2
A comprehensive analysis through Mendelian randomization of immunological markers and sphingolipid metabolism.通过孟德尔随机化对免疫标记物和鞘脂代谢进行综合分析。
Discov Oncol. 2025 Jul 28;16(1):1430. doi: 10.1007/s12672-025-03224-5.
3
GLP-1 RA Use and Major Adverse Cardiovascular Events in Patients With Monoclonal Gammopathy of Undetermined Significance.意义未明的单克隆丙种球蛋白病患者中胰高血糖素样肽-1受体激动剂的使用与主要不良心血管事件
JAMA Netw Open. 2025 Jun 2;8(6):e2517541. doi: 10.1001/jamanetworkopen.2025.17541.
4
Causal relationships between immune cell subtypes and risk of Pneumocystis pneumonia and lung cancer: a Mendelian randomization study.免疫细胞亚型与肺孢子菌肺炎和肺癌风险之间的因果关系：一项孟德尔随机化研究
Discov Oncol. 2025 Jun 6;16(1):1014. doi: 10.1007/s12672-025-02875-8.
5
Potential Use of GLP-1 and GIP/GLP-1 Receptor Agonists for Respiratory Disorders: Where Are We at?胰高血糖素样肽-1（GLP-1）及胃抑肽/胰高血糖素样肽-1（GIP/GLP-1）受体激动剂在呼吸系统疾病中的潜在应用：我们目前进展如何？
Medicina (Kaunas). 2024 Dec 9;60(12):2030. doi: 10.3390/medicina60122030.
本文引用的文献
1
Cancer statistics, 2024.2024年癌症统计数据。
CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. doi: 10.3322/caac.21820. Epub 2024 Jan 17.
2
GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity.在初治的2型糖尿病患者中，无论有无超重/肥胖，GLP-1受体激动剂与结直肠癌风险
JAMA Oncol. 2024 Feb 1;10(2):256-258. doi: 10.1001/jamaoncol.2023.5573.
3
A global federated real-world data and analytics platform for research.一个用于研究的全球联合真实世界数据与分析平台。
JAMIA Open. 2023 May 13;6(2):ooad035. doi: 10.1093/jamiaopen/ooad035. eCollection 2023 Jul.
4
Lung Cancer Patients' Characteristics and Comorbidities Using the Korean National Hospital Discharge In-depth Injury Survey Data.利用韩国国家医院出院深度伤害调查数据探讨肺癌患者的特征和合并症。
J Epidemiol Glob Health. 2022 Sep;12(3):258-266. doi: 10.1007/s44197-022-00044-6. Epub 2022 Jun 1.
5
Differential Risk of Cancer Associated with Glucagon-like Peptide-1 Receptor Agonists: Analysis of Real-world Databases.胰高血糖素样肽-1 受体激动剂相关癌症风险的差异：真实世界数据库分析。
Endocr Res. 2022 Feb;47(1):18-25. doi: 10.1080/07435800.2021.1955255. Epub 2021 Aug 30.
6
Obesity and incidence of lung cancer: a meta-analysis.肥胖与肺癌发病率：一项荟萃分析。
Int J Cancer. 2013 Mar 1;132(5):1162-9. doi: 10.1002/ijc.27719. Epub 2012 Jul 30.
7
The association of diabetes mellitus with liver, colon, lung, and prostate cancer is independent of hypertension, hyperlipidemia, and gout in Taiwanese patients.在台湾地区患者中，糖尿病与肝癌、结肠癌、肺癌和前列腺癌的相关性独立于高血压、高血脂和痛风。
Metabolism. 2012 Feb;61(2):242-9. doi: 10.1016/j.metabol.2011.06.020. Epub 2011 Aug 4.
Zotero 插件